Atlas Trials

Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients

Clinical trial NCT05929885 · RECRUITING

Trial details

NCT number
NCT05929885
Sponsor
National Cancer Centre, Singapore
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Pancreatic Cancer
Start date
2023-08-30
Primary completion
2027-02-28
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.